Puma Biotechnology Inc

PBYI's Fundamental analysis

Select the Comparisons :

None ▼

Select the Ratio:

None▼

None ▼

None▼

PBYI Growth rates comparisons

Puma Biotechnology Inc 's sales fell by -32.36 % in the third quarter of 2025 from the same quarter a year ago. Ranking at No. 396

Major Pharmaceutical Preparations industry recorded growth of revenues by 10.29 %

Puma Biotechnology Inc 's net profit decreased by -56.47 % in third quarter of 2025 year on year, to $9 millions.

• More on PBYI's Growth

PBYI's Valuation comparisons

Puma Biotechnology Inc
current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.

Puma Biotechnology Inc PEG ratio is at 0.06 Puma Biotechnology Inc realized cash reduction of $ -0.27 per share in trailing twelve-month period.

Company

6.99

PE TTM

Industry

PE TTM

Company's Price to Sales ratio is at 1.21.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.86.

• More on PBYI's Valuation

Total Debt (Millions $)	34
Dividend TTM ($)	0 $
Dividend Yield TTM (%)	-
Revenue/Employee (TTM) $	460,859
Net Income/Employee (TTM) $	80,387
Receivable Turnover (TTM)	7.27
Tangible Book Value (Per Share $)	1.40

PBYI's Valuation comparisons

Puma Biotechnology Inc
current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.

Puma Biotechnology Inc PEG ratio is at 0.06 Puma Biotechnology Inc realized cash outflow of $ -0.27per share in trailing twelve-month period.

Company

6.99

PE TTM

Industry

PE TTM

Company's Price to Sales ratio is at 1.21.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.86.

Puma Biotechnology Inc Price to Book Ratio is at 2.23 lower than Industry Avg. of 39.14. and higher than S&P 500 Avg. of 0.02

• More on PBYI's Valuation

• Market Capitalization (Millions $)	257
• Shares Outstanding (Millions)	51
• Employees	460
• Revenues (TTM) (Millions $)	212
• Net Income (TTM) (Millions $)	37
• Cash Flow (TTM) (Millions $)	-14
• Capital Exp. (TTM) (Millions $)	0
• Total Debt (Millions $)	34
• Dividend TTM ($)	0 $
• Dividend Yield TTM (%)	-
• Revenue/Employee (TTM) $	460,859
• Net Income/Employee(TTM) $	80,387
• Receivable Turnover Ratio (TTM)	7.27
• Tangible Book Value (Per Share $)	1.40

• Market Capitalization (Millions $)	257
• Shares Outstanding (Millions)	51
• Employees	460
• Revenues (TTM) (Millions $)	212
• Net Income (TTM) (Millions $)	37
• Cash Flow (TTM) (Millions $)	-14
• Capital Exp. (TTM) (Millions $)	0

PBYI's Profitability Comparisons

Puma Biotechnology Inc achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in third quarter of 2025 to 17.57 % from 12.66 % in II. Quarter.

Puma Biotechnology Inc net profit margin of 16.23 % is currently ranking no. 21 in Major Pharmaceutical Preparations industry, ranking no. 44 in Healthcare sector and number 553 in S&P 500.

Profitability by Segment
Total	16.23 %

	*Ratio*
• Capital Ratio (MRQ)	1.74
• Total Debt to Equity (MRQ)	0.29
• Tangible Leverage Ratio (MRQ)	1.16
• Asset Turnover Ratio (TTM)	1.05
• Inventory Turnover Ratio (TTM)	5.51

PBYI's Profitability Comparisons

Help

About us

Terms of Use

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.